Arvinas

Pharma’s ‘it’ therapy — a new drug class gaining steam
Pharma Voice
Wed, 09/4/24 - 11:30 am
protein degradation
Arvinas
Merck KGaA
Sanofi
Pfizer
Novartis
Pfizer, Arvinas Post Upbeat Data From Breast Cancer Study
NASDAQ
Thu, 05/16/24 - 09:54 pm
Pfizer
Arvinas
clinical trials
vepdegestrant
Ibrance
breast cancer
Novartis pays $150M for Arvinas' phase 3-ready prostate cancer protein degrader
Fierce Biotech
Thu, 04/11/24 - 11:56 am
Novartis
Arvinas
protein degradation
prostate cancer
Pfizer's $1B protein degradation bet yields 3% response rate in Arvinas' midphase breast cancer trial
Fierce Biotech
Tue, 11/22/22 - 11:00 am
Pfizer
protein degradation
Arvinas
clinical trials
breast cancer
ARV-471
AstraZeneca's Alexion, Arvinas nab space at future 10-story biotech tower in New Haven
Fierce Biotech
Mon, 04/18/22 - 10:48 am
AstraZeneca
Alexion
Arvinas
Connecticut
ASCO-GU – Arvinas sees the path to a prostate cancer niche
EP Vantage
Wed, 02/16/22 - 10:26 am
Arvinas
ARV-110
prostate cancer
ASCO-GU
Licensing deals rack up in 2021
EP Vantage
Fri, 12/10/21 - 10:46 am
licensing
GSK
Alector
Novartis
BeiGene
Pfizer
Arvinas
iTeos Therapeutics
Bristol Myers Squibb
Eisai
The search for a better Faslodex continues
EP Vantage
Mon, 07/26/21 - 10:12 pm
breast cancer
drug development
Serds
Pfizer
Arvinas
Pfizer funnels $1B into protein degrader Arvinas, with more in biobucks on the table
Fierce Biotech
Thu, 07/22/21 - 11:15 am
Pfizer
Arvinas
breast cancer
protein degradation
biobucks
ASCO: Arvinas unveils first-in-human data for novel protein degrader in prostate cancer
Fierce Biotech
Thu, 05/14/20 - 11:56 am
ASCO 2020
Arvinas
ARV-110
protein degradation
prostate cancer
2 Biotech Stocks That Soared Last Week
Motley Fool
Mon, 10/28/19 - 10:34 am
Biogen
Arvinas
aducanumab
protein degradation
ARV-110
Big Pharma Bets on Body’s Garbage-Disposal System to Beat Cancer
Bloomberg
Thu, 10/10/19 - 07:55 pm
cancer
Arvinas
Kymera
targeted protein degradation
Bayer inks Arvinas deal to develop protein degraders
Fierce Biotech
Tue, 06/4/19 - 11:56 am
Bayer
Arvinas
targeted protein degradation
Nasdaq triple IPO play brings in $345M as the big biotech party rocks on
Endpoints
Thu, 09/27/18 - 11:55 am
NASDAQ
IPOs
Entasis
Urovant Sciences
Arvinas
Sutro BioPharma
Sutro Biopharma, Arvinas Are Latest to Tee Up Biotech IPOs
Xconomy
Thu, 08/30/18 - 11:46 pm
biotech
IPOs
Sutro BioPharma
Arvinas
cancer
Pfizer lines up an $830M alliance with Arvinas on protein degradation
Endpoints
Thu, 01/4/18 - 11:23 am
Pfizer
Arvinas
targeted protein degradation
drug development
Genentech inks $650M deal with protein degradation pioneer Arvinas
Endpoints
Wed, 11/15/17 - 11:10 am
Genentech
targeted protein degradation
Arvinas
R&D
From big biopharma to biotech CEO, John Houston’s R&D journey highlights a fast-changing world
Endpoints
Wed, 09/20/17 - 09:23 am
R&D
John Houston
Big Pharma
biotech
Arvinas
GSK
Bristol-Myers Squibb
The 2015 Fierce 15 biotech execs take a bow
Fierce Biotech
Sat, 10/3/15 - 02:01 pm
Alector
Arvinas
CRISPR Therapeutics
Intellia Therapeutics
NGM Biopharmaceuticals
Padlock Therapeutics
SQZ Biotech
Revolution Medicines
Syros Pharmaceuticals
Unum Therapeutics
Yumanity Therapeutics
FierceBiotech's 2015 Fierce 15
Fierce Biotech
Wed, 09/30/15 - 09:51 am
Alector
Arvinas
Cell Medica
CRISPR Therapeutics
Denali Therapeutics
Intellia Therapeutics
MyoKardia
NGM Biopharmaceuticals
Padlock Therapeutics
Revolution Medicines SQZ Biotech
Surface Oncology
Syros Pharmaceuticals
Unum Therapeutics
Yumanity Therapeutics

Pages